Anumana has expanded its diagnostic ECG-AI technology into perioperative and acute cardiac care, bolstered by a new investment from Boston Scientific. The funding, part of Anumana’s Series C round, will accelerate the development of its multimodal generative AI platform and software as a medical device (SaMD).
The company plans to develop advanced AI imaging and visualization technologies aimed at improving precision in complex cardiac interventions. These will include real-time imaging platforms and predictive algorithms for procedures in structural heart, interventional cardiology, and electrophysiology. Boston Scientific will also collaborate with Anumana to create AI solutions for electrophysiology procedures, such as cardiac ablation and left atrial appendage closure.
Follow MEDWIRE.AI for more on innovations in AI-powered cardiovascular diagnostics.
